ArticleCureus2025
Calcitriol as a Therapeutic Strategy for Ferric Carboxymaltose-Induced Hypophosphatemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reply to Çevik et al. Comment on "Inghilleri, G.; Franchini, M. Hypophosphatemia in Patients Receiving Intravenous Iron Supplementation for Iron-Deficiency Anemia: A Narrative Review.Journal of clinical medicine · 2026Article
- Comment on Inghilleri, G.; Franchini, M. Hypophosphatemia in Patients Receiving Intravenous Iron Supplementation for Iron-Deficiency Anemia: A Narrative Review.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe an 83-year-old man with idiopathic protein-losing enteropathy on chronic total parenteral nutrition who developed profound, persistent hypophosphatemia after intravenous ferric carboxymaltose (FCM) infusion for anemia. His course was notable for hypophosphatemia refractory to phosphate supplementation, accompanied by hypocalcemia, secondary hyperparathyroidism, suppressed 1,25-dihydroxy vitamin D, and markedly elevated fibroblast growth factor 23 (FGF23). These findings were consistent with FCM-induced hypophosphatemia, a condition increasingly recognized as part of the "6H Syndrome." Initiation of oral calcitriol led to rapid normalization of calcium and phosphate levels and enabled long-term stability without further IV iron exposure. This case underscores the need for heightened clinical awareness of FCM-associated electrolyte disturbances, especially in patients with baseline malnutrition or malabsorptive disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.